Combination therapy in kidney cancer: the next revolution?
Mené sur 153 patients atteints d'un carcinome rénal métastatique, cet essai international randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du lenvatinib et de l'évérolimus, seuls ou en combinaison, en traitement de deuxième ligne
Treatment of renal cell carcinoma seems to be at the dawn of a golden era. Through re-evaluation of the immunological paradigm, the focus has shifted to new immunomodulators as promising agents for future treatment of metastatic disease. Results of studies with PD-1 inhibitors have attracted the attention of experts worldwide. However, in The Lancet Oncology, Robert Motzer and colleagues report findings of a randomised phase 2 study that reopens the hypothesis—until now rejected by several negative studies—of a synergistic combination of VEGF receptor tyrosine kinase inhibitors and mTOR inhibitors for the treatment of metastatic renal cell carcinoma.